Cite
Furuhashi M, Sakuma I, Morimoto T, et al. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. J Atheroscler Thromb. 2020;29(1):24-37doi: 10.5551/jat.58396.
Furuhashi, M., Sakuma, I., Morimoto, T., Higashiura, Y., Sakai, A., Matsumoto, M., Sakuma, M., Shimabukuro, M., Nomiyama, T., Arasaki, O., Node, K., & Ueda, S. (2022). Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Journal of atherosclerosis and thrombosis, 29(1), 24-37. https://doi.org/10.5551/jat.58396
Furuhashi, Masato, et al. "Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy." Journal of atherosclerosis and thrombosis vol. 29,1 (2022): 24-37. doi: https://doi.org/10.5551/jat.58396
Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. J Atheroscler Thromb. 2022 Jan 01;29(1):24-37. doi: 10.5551/jat.58396. Epub 2020 Dec 18. PMID: 33342939.
Copy
Download .nbib